Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management.
Visceral leishmaniasis (VL) is a rare complication of kidney transplantation, with <100 cases reported in the literature. It is a life-threatening condition and usually occurs as a late complication after transplantation, with a median delay of 18 months between transplantation and onset of disease. We report the clinical features and management of 5 kidney transplant recipients who presented with VL in the early post-transplant period. All patients were successfully treated with liposomal amphotericin B (L-AMB), but 2 patients experienced graft loss. VL should be considered in the differential diagnosis in kidney transplant recipients living in endemic areas, who present with unexplained fever and pancytopenia in the early post-transplant period. Leishmania serology should be included in the screening of all transplant recipients, in order to identify a group of patients who could benefit from preemptive anti-Leishmania therapy. Therapy with L-AMB is highly effective and well tolerated in kidney transplant recipients with VL.
Veroux
M
M
Department of Surgery, Transplantation, University Hospital of Catania, Catania, Italy. veroux@unict.it
Corona
D
D
Giuffrida
G
G
Cacopardo
B
B
Sinagra
N
N
Tallarita
T
T
Giaquinta
A
A
Zerbo
D
D
Veroux
P F
PF
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D007898:Leishmaniasis, Visceral / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
C068538:liposomal amphotericin B; D000666:Amphotericin B